Nurix Therapeutics, Inc. (NRIX) CSO exercises 4,356 options, sells shares
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 4,356 shares at an exercise price of $1.8600 per share and sold 4,356 common shares at $25.0000 per share on August 5, 2026 under a Rule 10b5-1 trading plan. After the exercise, 62,310 options from this grant remained outstanding, with an option expiration date of 2029-08-28.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,356 shares ($101K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Hansen Gwenn
Role
Chief Scientific Officer
Sold
4,356 shs ($109K)
Approx. gross sale proceeds
$109K
Approx. exercise cost
$8K
Approx. pre-tax spread
$101K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F1, F2 | 4,356 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 4,356 | $1.86 | $8K |
| Sale | Common Stock F1 | 4,356 | $25.00 | $109K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 62,310 shares (Direct);
Common Stock — 117,227 shares (Direct)
Footnotes (2)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- F2. The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.
Key Figures
Options exercised: 4356 shares
Exercise price: 1.8600
Shares sold: 4356 shares
+3 more
6 metrics
Options exercised
4356 shares
Employee stock options exercised on 2026-08-05 by CSO Gwenn Hansen
Exercise price
1.8600
Per-share exercise price for employee stock options converted into common stock
Shares sold
4356 shares
Common shares sold on 2026-08-05 following option exercise
Sale price
25.0000
Per-share price for 4,356 common shares sold by Gwenn Hansen
Options remaining
62310 options
Employee stock options remaining after the 4,356-option exercise from the same grant
Option expiration
2029-08-28
Expiration date for the employee stock option grant reported as a derivative security
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (right to buy), derivative security, vested as to 1/48
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy) for company shares"
derivative security financial
"Exercise or conversion of derivative security reported under transaction code M"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vested as to 1/48 financial
"The stock option vested as to 1/48 of the total shares monthly"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Nurix Therapeutics (NRIX) disclose for Gwenn Hansen?
Nurix Therapeutics disclosed that CSO Gwenn Hansen exercised options for 4,356 shares and sold 4,356 common shares on August 5, 2026. The Form 4 shows an option exercise followed by a same-day share sale reported as direct ownership.
How many Nurix Therapeutics (NRIX) options does Gwenn Hansen retain after this transaction?
Following the reported exercise of 4,356 options, Gwenn Hansen holds 62,310 employee stock options from this grant. This remaining derivative position is shown as the total options following the transaction, with the grant expiring on 2029-08-28.
What is the vesting schedule of the exercised NRIX stock options for Gwenn Hansen?
The exercised stock option vested as to 1/48 of the total shares monthly, beginning June 10, 2019. According to the disclosure, the option was fully vested by May 10, 2023, before the August 5, 2026 exercise and sale transactions occurred.
Were Gwenn Hansen’s NRIX trades made under a Rule 10b5-1 trading plan?
Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Gwenn Hansen, and the Rule 10b5-1 checkbox is affirmed. This indicates the trades followed a pre-established plan rather than discretionary timing.